News Roundup [abridged Versions Appear In The Paper Journal]

Docetaxel prolongs life in men with hormone refractory prostate cancer

BMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7471.877 (Published 14 October 2004) Cite this as: BMJ 2004;329:877
  1. Scott Gottlieb
  1. New York

Docetaxel (Taxotere) in combination with prednisolone helps men with advanced, hormone refractory prostate cancer live longer and enjoy more time free of pain, compared with mitoxantrone and prednisone, the current standard treatment for these patients, a US study shows.

Treatment with mitoxantrone and prednisone is known to reduce pain and improves the quality of life in men with advanced, hormone refractory prostate cancer, but it has never been shown to improve survival.

The study's researchers, led by Dr Ian Tannock from the Department of Medical Oncology and Hematology at Princess Margaret Hospital in Toronto, set out to determine whether docetaxel prolongs lives (New England Journal of Medicine 2004;354:1502-12).

The researchers …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe